These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
211 related articles for article (PubMed ID: 12119798)
21. Effects of renin-angiotensin system inhibition on end-organ protection: can we do better? Weir MR Clin Ther; 2007 Sep; 29(9):1803-24. PubMed ID: 18035185 [TBL] [Abstract][Full Text] [Related]
22. [Does the rennin inhibitor aliskiren offer promising novel opportunities in the treatment of cardiovascular diseases?]. Horký K Vnitr Lek; 2007 Apr; 53(4):364-70. PubMed ID: 17578167 [TBL] [Abstract][Full Text] [Related]
24. Ambulatory blood pressure monitoring and organ damage. Mancia G; Parati G Hypertension; 2000 Nov; 36(5):894-900. PubMed ID: 11082163 [TBL] [Abstract][Full Text] [Related]
25. Pulse pressure, arterial stiffness, and cardiovascular risk. Safar ME Curr Opin Cardiol; 2000 Jul; 15(4):258-63. PubMed ID: 11139089 [TBL] [Abstract][Full Text] [Related]
26. The 2006 Canadian Hypertension Education Program recommendations for the management of hypertension: Part II - Therapy. Khan NA; McAlister FA; Rabkin SW; Padwal R; Feldman RD; Campbell NR; Leiter LA; Lewanczuk RZ; Schiffrin EL; Hill MD; Arnold M; Moe G; Campbell TS; Herbert C; Milot A; Stone JA; Burgess E; Hemmelgarn B; Jones C; Larochelle P; Ogilvie RI; Houlden R; Herman RJ; Hamet P; Fodor G; Carruthers G; Culleton B; Dechamplain J; Pylypchuk G; Logan AG; Gledhill N; Petrella R; Tobe S; Touyz RM; Can J Cardiol; 2006 May; 22(7):583-93. PubMed ID: 16755313 [TBL] [Abstract][Full Text] [Related]
27. Basic science: hypertensive target organ damage. Bidani AK; Griffin KA J Am Soc Hypertens; 2015 Mar; 9(3):235-7; quiz 238. PubMed ID: 25670252 [No Abstract] [Full Text] [Related]
28. Guidelines for management of hypertension: report of the third working party of the British Hypertension Society. Ramsay L; Williams B; Johnston G; MacGregor G; Poston L; Potter J; Poulter N; Russell G J Hum Hypertens; 1999 Sep; 13(9):569-92. PubMed ID: 10482967 [TBL] [Abstract][Full Text] [Related]
30. [Relation between changes in retinal microcirculation and other organ damage in hypertension and regression with antihypertensive treatment]. Pose-Reino A; Rodríguez-Fernández M; Hayik B; Goméz-Ulla Irazabal F; Carrera-Nouche MJ; González-Barcala J; Méndez-Naya I; Estévez-Núñez JC Med Clin (Barc); 2007 Apr; 128(16):605-8. PubMed ID: 17524317 [TBL] [Abstract][Full Text] [Related]
31. Molecular Interactions of Arterial Hypertension in Its Target Organs. Kućmierz J; Frąk W; Młynarska E; Franczyk B; Rysz J Int J Mol Sci; 2021 Sep; 22(18):. PubMed ID: 34575833 [TBL] [Abstract][Full Text] [Related]
32. The 2001 Canadian recommendations for the management of hypertension: Part one--Assessment for diagnosis, cardiovascular risk, causes and lifestyle modification. Zarnke KB; McAlister FA; Campbell NR; Levine M; Schiffrin EL; Grover S; McKay DW; Myers MG; Wilson TW; Rabkin SW; Feldman RD; Burgess E; Bolli P; Honos G; Lebel M; Mann K; Abbott C; Tobe S; Petrella R; Touyz RM; Can J Cardiol; 2002 Jun; 18(6):604-24. PubMed ID: 12107419 [TBL] [Abstract][Full Text] [Related]
33. [Inhibition of the renin-angiotensin system to prevent target organ damage: the "renal continuum"]. Tislér A Orv Hetil; 2003 May; 144(18 Suppl 1):898-901. PubMed ID: 12785234 [TBL] [Abstract][Full Text] [Related]
34. Spotlight on renin. Mechanisms of hypertension-induced target organ damage. Müller DN J Renin Angiotensin Aldosterone Syst; 2007 Sep; 8(3):148-50. PubMed ID: 17907104 [No Abstract] [Full Text] [Related]
35. Reduced hypertension-induced end-organ damage in mice lacking cardiac and renal angiotensinogen synthesis. Kang N; Walther T; Tian XL; Bohlender J; Fukamizu A; Ganten D; Bader M J Mol Med (Berl); 2002 Jun; 80(6):359-66. PubMed ID: 12072911 [TBL] [Abstract][Full Text] [Related]
36. Novel Biomarkers to Detect Target Organ Damage in Acute Hypertension. Boone S; Kuo D Curr Hypertens Rep; 2018 Mar; 20(3):21. PubMed ID: 29556795 [TBL] [Abstract][Full Text] [Related]
37. The 2007 Canadian Hypertension Education Program recommendations for the management of hypertension: part 2 - therapy. Khan NA; Hemmelgarn B; Padwal R; Larochelle P; Mahon JL; Lewanczuk RZ; McAlister FA; Rabkin SW; Hill MD; Feldman RD; Schiffrin EL; Campbell NR; Logan AG; Arnold M; Moe G; Campbell TS; Milot A; Stone JA; Jones C; Leiter LA; Ogilvie RI; Herman RJ; Hamet P; Fodor G; Carruthers G; Culleton B; Burns KD; Ruzicka M; deChamplain J; Pylypchuk G; Gledhill N; Petrella R; Boulanger JM; Trudeau L; Hegele RA; Woo V; McFarlane P; Touyz RM; Tobe SW; Can J Cardiol; 2007 May; 23(7):539-50. PubMed ID: 17534460 [TBL] [Abstract][Full Text] [Related]
38. The 2004 Canadian recommendations for the management of hypertension: Part II--Therapy. Khan NA; McAlister FA; Campbell NR; Feldman RD; Rabkin S; Mahon J; Lewanczuk R; Zarnke KB; Hemmelgarn B; Lebel M; Levine M; Herbert C; Can J Cardiol; 2004 Jan; 20(1):41-54. PubMed ID: 14968142 [TBL] [Abstract][Full Text] [Related]
39. [Arterial hypertension and dyslipidemia in patients with chronic kidney disease (CKD). Anti-platelet aggregation. Goal oriented treatment]. Cases Amenós A; Goicoechea Diezhandiño M; de Alvaro Moreno F Nefrologia; 2008; 28 Suppl 3():39-48. PubMed ID: 19018737 [TBL] [Abstract][Full Text] [Related]
40. Treatment of hypertension based on measurement of blood pressure variability: lessons from animal studies. Su DF Curr Opin Cardiol; 2006 Sep; 21(5):486-91. PubMed ID: 16900013 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]